Spoor Johan M. 4
4 · AzurRx BioPharma, Inc. · Filed Jul 16, 2018
Insider Transaction Report
Form 4
Spoor Johan M.
DirectorPresident and CEO
Transactions
- Award
Common Stock
2018-07-12+200,000→ 300,034 total
Holdings
- 39,851(indirect: By Children)
Common Stock
Footnotes (1)
- [F1]Represents grant of restricted stock. Shares shall vest in increments as follows: (i) 1/6 upon the acceptance of a U.S. IND for MS 1819; (ii) 1/6 upon the the first CF patient dosed with MS1819 anywhere in the globe; (iii) 1/6 upon upon enrollment of the first 30 patients in a CF trial; (iv) 1/6 on July 12, 2019; (v) 1/6 on July 12, 2020; and (vi) 1/6 on July 12, 2021.